Oral Retention Device for Controlled-Release Levodopa

Solution Overview

Problem

Current extended release drugs fail to provide prolonged and steady plasma profiles for active pharmaceutical ingredients, particularly levodopa, leading to motor complications in Parkinson's disease patients, and existing oral retention devices are invasive or prone to accidental tablet drop and suffocation risks.

Innovation Solution

A controlled-release system comprising an extended release platform with a retention enabling platform, where the platform includes a tablet core coated with cellulose acetate and copovidone, and an oral retention device that securely holds the medicinal tablet in the oral cavity using a tooth-matching component, preventing accidental drop and ensuring stable drug release.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If conventional extended-release dosage forms are used, then the drug release duration is extended, but the bioavailability is compromised and therapeutic coverage is not prolonged

Engineering Contradiction:
Core Design Contradiction:
Duration of action of moving objectVSReliability

Solution Approach 1:

The dosage form is segmented into multiple functional layers: a biodegradable polymer matrix for controlled drug release, a hydrophilic coating layer for gastric retention, and a protective outer layer. This segmentation allows each layer to perform its specific function optimally, achieving both prolonged release and maintained bioavailability.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent employs composite materials including biodegradable polymers (PLA, PLGA), hydrophilic polymers (carboxymethyl cellulose, hydroxypropyl methyl cellulose), and protective coatings. These composite materials work synergistically to provide controlled release, enhance gastric retention, and protect the drug formulation, thereby resolving the contradiction between extended duration and maintained bioavailability.

Inventive Principle:
Principle #40Composite materials

2Duration of action of moving object

If oral retention devices are used to extend retention time, then therapeutic coverage is prolonged, but the devices are invasive or prone to accidental tablet drop and suffocation risks

Engineering Contradiction:
Core Design Contradiction:
Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The dosage form is designed to be self-retaining through its physical properties. The hydrophilic coating layer automatically adheres to the gastric mucosa through hydrogen bonding and van der Waals forces, providing retention without requiring external mechanical devices. This self-service approach eliminates invasiveness and associated safety risks while maintaining prolonged retention time.

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The patent uses a flexible hydrophilic coating layer (thin film) that can adapt to the gastric mucosa surface. This flexible film provides retention through surface adhesion rather than mechanical confinement, eliminating the need for invasive retention devices and their associated risks of accidental drop or suffocation.

Inventive Principle:
Principle #30Flexible shells and thin films

3Reliability

If levodopa is administered with decarboxylase inhibitors, then the dopamine content in the brain is increased, but motor complications such as on-off phenomena and dyskinesia occur

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The biodegradable polymer matrix provides continuous, sustained release of levodopa over extended periods. This continuous action maintains stable plasma concentrations, preventing the pulsatile stimulation that causes motor complications while ensuring adequate dopamine supply to the brain throughout the dosing interval.

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

The patent modifies the release parameters of levodopa by controlling the biodegradation rate of the polymer matrix and adjusting the hydrophilic coating properties. This changes the release kinetics from rapid to sustained, maintaining optimal dopamine levels while reducing peak concentrations that trigger motor complications.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The system provides stable and prolonged drug release, improving bioavailability and reducing motor complications in Parkinson's disease patients while being non-invasive and safe, with the ability to replace the drug platform as needed for continuous therapy.

Implementation Method 1

a coating membrane comprising cellulose acetate and copovidone

Methodology Applied
Scientific EffectDiffusion: Diffusion

Implementation Method 2

extended release platform with a tablet core and a coating membrane

Methodology Applied
Scientific EffectErosion: Erosion

Implementation Method 3

muco-adhesion (U.S. Pat. No. 6,207,197 and US2005/030552)

Methodology Applied
Scientific EffectMuco-adhesion: Adhesive

Implementation Method 4

an osmotic pump delivery system including LD and CD

Methodology Applied
Scientific EffectOsmosis: Osmosis

Data Source

PatentUS11911513B2Controlled-release system of active pharmaceutical ingredient and preparation method therefor
Publication Date: 2024.02.27
  • US11911513B2 patent drawing
  • US11911513B2 patent drawing
  • US11911513B2 patent drawing

AI summary

Disclosed are a controlled-release dosage form with an absorption window in the upper gastrointestinal tract and a preparation method therefor, wherein the controlled-release dosage form comprises a controlled-release platform and a retention platform. The controlled-release platform is a pharmaceutical composition comprising a tablet core and a coating membrane; and the retention platform holds the controlled-release platform in the oral cavity. The operation steps of the controlled-release dosage form are as follows: placing the controlled-release platform in the retention platform, and fixing the retention platform on matching teeth in the oral cavity; taking out the controlled-release dosage form after 4-24 hours and replacing same with a new controlled-release platform; and re-fixing the retention platform on the matching teeth in the oral cavity to achieve the sustained and stable release of drugs.